Publication: Treatment of Chronic Hepatitis C in Special Populations
Issued Date
2015-12-01
Resource Type
ISSN
15581942
08898553
08898553
Other identifier(s)
2-s2.0-84947616929
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Gastroenterology Clinics of North America. Vol.44, No.4 (2015), 883-900
Suggested Citation
Chalermrat Bunchorntavakul, Tawesak Tanwandee Treatment of Chronic Hepatitis C in Special Populations. Gastroenterology Clinics of North America. Vol.44, No.4 (2015), 883-900. doi:10.1016/j.gtc.2015.06.002 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36234
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment of Chronic Hepatitis C in Special Populations
Author(s)
Other Contributor(s)
Abstract
© 2015 Elsevier Inc. The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by expert guidelines. The treatment regimens and sustained virological response rates for special populations are nearly similar to those of the general HCV population. Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease.